Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Joshua Evans

Physician Assistant Winter Park, FL Physician Assistant

NPI 1699484659 CMS profile 11406687

460 N Orlando Ave Ste 200, Winter Park, FL 32789

Open in the dashboard

General payments

$6,789

299 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Evans of Winter Park, FL is reported in the CMS Open Payments database as having received $6,789 across 299 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,980 104
2024 General $1,745 84
2023 General $1,984 106
2022 General $81 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Evans
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Joshua Evans were reported at $2,980. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Joshua Evans Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $81 $155 $48–$522 $149
2023 $1,984 $167 $52–$557 $160
2024 $1,745 $178 $55–$600 $164
2025 $2,980 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $1,129 18 payments
  2. Celgene Corporation $513 30 payments
  3. Novartis Pharmaceuticals Corporation $465 27 payments
  4. Janssen Biotech, Inc. $444 27 payments
  5. Merck Sharp & Dohme Corporation $341 14 payments
  6. Daiichi Sankyo Inc. $339 16 payments
  7. Pfizer Inc. $281 14 payments
  8. Incyte Corporation $264 11 payments
  9. Astellas Pharma US Inc $224 12 payments
  10. Lilly USA, LLC $203 8 payments
  11. Other $2,585 122 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,018 295 payments
  2. Consulting Fee $650 1 payment
  3. Education $121 3 payments
Products named General payments · program years 2022–2025
  1. REBLOZYL $355 20 payments
  2. KEYTRUDA $341 14 payments
  3. ENHERTU Oncology $312 9 payments
  4. ENHERTU Oncology $266 12 payments
  5. KISQALI $246 15 payments
  6. RYBREVANT $222 13 payments
  7. RETEVMO $203 8 payments
  8. VERZENIO $203 8 payments
  9. JAYPIRCA $203 8 payments
  10. ERLEADA $197 11 payments
  11. Other $5,249 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

299 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record